Pazopanib

Catalog No.S3012 Synonyms: GW786034

Pazopanib Chemical Structure

Molecular Weight(MW): 437.52

Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 70 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Arch Toxicol, 2018, 92(4):1435-1451. Pazopanib purchased from Selleck.

    (a,b) Effect of Pazopanib on vascular network integrity. VMOs were exposed to drug from day 4 to 6. Data are normalized to day of first drug exposure and are shown as percentage of control. Error bars show mean ± s.d (n = 3) (p < 0.05 vs control).

    Sci Rep, 2016, 6:31589. Pazopanib purchased from Selleck.

  • J Virol 2011 85(5), 2296-303. Pazopanib purchased from Selleck.

    Three RCC cell lines treated with different concentrations of TKI and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib purchased from Selleck.

  • (B) The effects of AZD2014, BEZ235, lapatinib, LEE011, pazopanib on PI3K/AKT signaling in sarcoma PDC line were determined by immunoblotting analysis. Cells were treated with 1 μM of the indicated drugs for 72 h.

    Transl Oncol, 2016, 9(3):197-202. Pazopanib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] PPazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human EoL-1-cell cell M3LJTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUfJcohq[mm2aX;uJI9nKGi3bXHuJGVwVC1zLXPlcIwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiaXO1NF0zNjh7ZT2wOUDPxE1? MkTZV2FPT0WU
human AN3-CA cell M{XIUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkjZTY5pcWKrdHnvckBw\iCqdX3hckBCVjNvQ1GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNE4xPSCwTR?= MnLUV2FPT0WU
human CGTH-W-1 cell MoDCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmHQTY5pcWKrdHnvckBw\iCqdX3hckBET1SKLWetNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQxNjBzIH7N MmXkV2FPT0WU
human GDM-1 cell NH;rVoVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoeyTY5pcWKrdHnvckBw\iCqdX3hckBITE1vMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwN{46QSCwTR?= NFvVWXhUSU6JRWK=
human A204 cell M3vvd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkP0TY5pcWKrdHnvckBw\iCqdX3hckBCOjB2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUC5MlA3KG6P MVPTRW5ITVJ?
human G-402 cell M2q4TWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVTJcohq[mm2aX;uJI9nKGi3bXHuJGcuPDB{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NUOxMlg1KG6P M1jPdnNCVkeHUh?=
human MFE-296 cell NFz3[4FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4fWfWlvcGmkaYTpc44hd2ZiaIXtZY4hVU[HLUK5OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTlyMkKg{txO MonSV2FPT0WU
human NOS-1 cell NIfRcoJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV\Jcohq[mm2aX;uJI9nKGi3bXHuJG5QWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJIlkPTB;MD62OVk5PyEQvF2= NWezcnlpW0GQR1XS
human KG-1 cell M3fTVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGrKO4FKdmirYnn0bY9vKG:oIHj1cYFvKEuJLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlcyPzV3IN88US=> NX3Be3RXW0GQR1XS
human HT55 cell NVKwNFhwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NYLwWmpnUW6qaXLpeIlwdiCxZjDoeY1idiCKVEW1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46QDd6MTFOwG0> M3\KWXNCVkeHUh?=
human MG-63 cell Mk\sS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYDqd5ZUUW6qaXLpeIlwdiCxZjDoeY1idiCPRz22N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvODBzNE[g{txO MnrJV2FPT0WU
human CCF-STTG1 cell MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYjJcohq[mm2aX;uJI9nKGi3bXHuJGNETi2VVGTHNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F697zOIFnDOVA:OS5yNEm4NUDPxE1? NHvT[5VUSU6JRWK=
human RT-112 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4j5fGlvcGmkaYTpc44hd2ZiaIXtZY4hWlRvMUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4yODN5NjFOwG0> MkTFV2FPT0WU
human MC-IXC cell MkKyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVrJcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNVE2OTJizszN MVHTRW5ITVJ?
human HUTU-80 cell NFHPblVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWrJcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlI5OTB|IN88US=> NUfFOI9kW0GQR1XS
human MV-4-11 cell Mn\aS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3rXV2lvcGmkaYTpc44hd2ZiaIXtZY4hVVZvND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzR3MEGg{txO MVTTRW5ITVJ?
human LCLC-103H cell NEDzNFJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlW4TY5pcWKrdHnvckBw\iCqdX3hckBNS0yFLUGwN2gh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigQ>? M{fabHNCVkeHUh?=
human G-401 cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{PxU2lvcGmkaYTpc44hd2ZiaIXtZY4hTy12MEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlQ3PDJzIN88US=> NWW0XmZOW0GQR1XS
human A704 cell M4fsbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M122ZWlvcGmkaYTpc44hd2ZiaIXtZY4hSTdyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOlA{OjNizszN MlXqV2FPT0WU
human ESS-1 cell M{HWOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYDJcohq[mm2aX;uJI9nKGi3bXHuJGVUWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62NFM6PiEQvF2= M3nlRnNCVkeHUh?=
human HLE cell M2P0Smdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4D3[GlvcGmkaYTpc44hd2ZiaIXtZY4hUEyHIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62N|gxPCEQvF2= NWey[3VYW0GQR1XS
human NY cell NHPHSGRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXHJcohq[mm2aX;uJI9nKGi3bXHuJG5[KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS56NEiyNUDPxE1? M4To[3NCVkeHUh?=
human A427 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYrJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkm4NFc2KM7:TR?= M4S0UHNCVkeHUh?=
human SK-N-DZ cell MlvwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYfiRpFQUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OMWRbKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5yMkO4NUDPxE1? MoTSV2FPT0WU
human J82 cell M1WwTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWewZox6UW6qaXLpeIlwdiCxZjDoeY1idiCMOEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlA3ODh6IN88US=> MVrTRW5ITVJ?
human GI-1 cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHvxemtKdmirYnn0bY9vKG:oIHj1cYFvKEeLLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlIzQTVzIN88US=> M{DsVXNCVkeHUh?=
human NCI-H716 cell M13J[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mk\uTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEexOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOzF4M{Og{txO NXzTN4FjW0GQR1XS
human SF126 cell MnnES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXTJcohq[mm2aX;uJI9nKGi3bXHuJHNHOTJ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj60O|Q2QSEQvF2= MkK3V2FPT0WU
human H4 cell NX;rWYo3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYTJcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi53MUK2NkDPxE1? NYfzdJpXW0GQR1XS
human LB831-BLC cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYTXU2F4UW6qaXLpeIlwdiCxZjDoeY1idiCOQkizNU1DVENiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkW0OVY3KM7:TR?= M1HBeXNCVkeHUh?=
human HCC1395 cell M4HGUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYTJcohq[mm2aX;uJI9nKGi3bXHuJGhESzF|OUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlU5OTV4IN88US=> NG\WcmtUSU6JRWK=
human LK-2 cell NIfTNFBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVXNOWJjUW6qaXLpeIlwdiCxZjDoeY1idiCOSz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk43PDV4OTFOwG0> NVzsVWpFW0GQR1XS
human G-361 cell NXjwUJF6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M333OmlvcGmkaYTpc44hd2ZiaIXtZY4hTy1|NkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlA1ODh{IN88US=> MnziV2FPT0WU
human NCI-H2342 cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWj5d5AzUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI{PDJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeT6gTWM2OD1|LkGzN|E3KM7:TR?= M4LWZXNCVkeHUh?=
human SK-LU-1 cell  M4f6b2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXzReYQzUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3MWU0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5zOEe2O{DPxE1? NH\XfYlUSU6JRWK=
human IGROV-1 cell  M1XhWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NETB[XRKdmirYnn0bY9vKG:oIHj1cYFvKEmJUl;WMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjJ2N{GzJO69VQ>? NHT4VFhUSU6JRWK=
human EB2 cell MoGyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXXJcohq[mm2aX;uJI9nKGi3bXHuJGVDOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwMkixOlgh|ryP M1XJRXNCVkeHUh?=
human CAL-54 cell M2H1UGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEnhPWZKdmirYnn0bY9vKG:oIHj1cYFvKEODTD21OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOjh|Nkeg{txO NWfSXGZvW0GQR1XS
human LB1047-RCC cell NGfacppIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3rDPGlvcGmkaYTpc44hd2ZiaIXtZY4hV0OXQj3NJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4{OzF|Nkig{txO Mo\JV2FPT0WU
Daudi cell M3zLTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmWwTY5pcWKrdHnvckBw\iCqdX3hckBNSjFyNEetVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy53M{G2OEDPxE1? M{\TVXNCVkeHUh?=
human Daudi cell MorpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHfO[oNKdmirYnn0bY9vKG:oIHj1cYFvKESjdXTpJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{43PjJzOTFOwG0> NH3GVVhUSU6JRWK=
human A172 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEXDTnNKdmirYnn0bY9vKG:oIHj1cYFvKEFzN{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlc{PzlizszN MmHuV2FPT0WU
human KGN cell NX63dVhwT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3nxbmlvcGmkaYTpc44hd2ZiaIXtZY4hU0eQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6wOlcxQSEQvF2= NEnWSGlUSU6JRWK=
human SNG-M cell Ml3tS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVXwbJdDUW6qaXLpeIlwdiCxZjDoeY1idiCVTletUUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvODh4Nkmg{txO M1LTfnNCVkeHUh?=
human SW1710 cell M3ri[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXnJXWZbUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjR5M{G4JO69VQ>? MXvTRW5ITVJ?
human HT29 cells NH;SOJVRem:uaX\ldoF1cW:wIHHzd4F6 MoPSRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVEK5JINmdGy|IHnuJJNmenWvIHPvcpRicW6rbnegcYVlcXWv MWmxPFYzODN6Mh?=
human A375P cells NXTSbog{WHKxbHnm[ZJifGmxbjDhd5NigQ>? M{\JW2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUO3OXAh[2WubIOgbY4he2W{dX2gZ49vfGGrbnnu[{Bu\WSrdX2= M13zflE5PjJyM{iy
human HN5 cells NG[1W4dRem:uaX\ldoF1cW:wIHHzd4F6 NVThVY8xSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUlUh[2WubIOgbY4he2W{dX2gZ49vfGGrbnnu[{Bu\WSrdX2= M4rtdFE5PjJyM{iy
HUVEC MlfwSpVv[3Srb36gZZN{[Xl? MkLVNUDPxE1? NGjFdWs3KGh? NYHLSIZCSW62aXHu[4lw\2WwaXOgZYN1cX[rdImgbY4hUFWYRVOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjD0eYJmKG[xcn3heIlwdiCjdDCwMlEhfU1iYX\0[ZIhPiCqcoOgZpkhVWG2cnnn[Ywh[XO|YYm= NHXFV3EzPDB|NkC0Ni=>
human Daoy cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGTWd2FKdmirYnn0bY9vKG:oIHj1cYFvKESjb4mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc4QTR7IN88US=> MX;TRW5ITVJ?
human DMS-273 cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoOwTY5pcWKrdHnvckBw\iCqdX3hckBFVVNvMkezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46PjJyMjFOwG0> M{HUXnNCVkeHUh?=
human KU812 cell MkXMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFrLc|dKdmirYnn0bY9vKG:oIHj1cYFvKEuXOEGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4{PzhzMjFOwG0> MlPkV2FPT0WU
human NCI-H727 cell MmXtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWHJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KN{K3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41ODlyMTFOwG0> NYS0d3A2W0GQR1XS
human P30-OHK cell MnezS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUfJcohq[mm2aX;uJI9nKGi3bXHuJHA{OC2RSFugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ3QTRizszN MmfrV2FPT0WU
human MIA-PaCa-2 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF\rfphKdmirYnn0bY9vKG:oIHj1cYFvKE2LQT3QZWNiNTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lk[wOFY3KM7:TR?= M3LlUnNCVkeHUh?=
human TT cell Mnf1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVHrOFBuUW6qaXLpeIlwdiCxZjDoeY1idiCWVDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOlYzPCEQvF2= M4[xbnNCVkeHUh?=
human DK-MG cell NXHNcmk5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoK3TY5pcWKrdHnvckBw\iCqdX3hckBFUy2PRzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|IxOjhizqzt MYfTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Animal Research:

[2]

+ Expand
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Formulation: --
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 87 mg/mL warmed (198.84 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 437.52
Formula

C21H23N7O2S

CAS No. 444731-52-6
Storage powder
in solvent
Synonyms GW786034

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03735758 Recruiting Soft Tissue Sarcoma Adult GWT-TUD GmbH November 2 2018 Phase 4
NCT03660930 Not yet recruiting Soft Tissue Sarcoma University of Washington October 25 2018 Phase 1|Phase 2
NCT03628131 Not yet recruiting Relapsed Pediatric Solid Tumor|Refractory Pediatric Solid Tumor Samsung Medical Center|Ministry of Health Republic of Korea October 2018 Phase 1|Phase 2
NCT03592472 Recruiting Renal Cell Carcinoma Xynomic Pharmaceuticals Inc. July 17 2018 Phase 3
NCT03275558 Withdrawn Recurrent Glioblastoma|Gliosarcoma|Anaplastic Gliomas Center Trials & Treatment July 17 2018 Phase 1
NCT03334409 Recruiting Clear Cell Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v8|Stage IV Renal Cell Cancer AJCC v7 Academic and Community Cancer Research United|National Cancer Institute (NCI) February 16 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

Related VEGFR Products0

Tags: buy Pazopanib | Pazopanib supplier | purchase Pazopanib | Pazopanib cost | Pazopanib manufacturer | order Pazopanib | Pazopanib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID